Online inquiry

IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6380MR)

This product GTTS-WQ6380MR is a type of mRNA modified with 2-Thio-UTP, which ecodes the monoclonal antibody that targets Factor IX substitute gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000133.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2158
UniProt ID P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ6380MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ972MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-368
GTTS-WQ5970MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CLLB8
GTTS-WQ8462MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HTI-1088
GTTS-WQ5270MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD124
GTTS-WQ7652MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GEN-1029
GTTS-WQ13919MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN2477
GTTS-WQ4330MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIVV009
GTTS-WQ14826MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SGN-75
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW